CN109311812A - 作为c-MET抑制剂的吡啶酮类化合物 - Google Patents
作为c-MET抑制剂的吡啶酮类化合物 Download PDFInfo
- Publication number
- CN109311812A CN109311812A CN201780036464.XA CN201780036464A CN109311812A CN 109311812 A CN109311812 A CN 109311812A CN 201780036464 A CN201780036464 A CN 201780036464A CN 109311812 A CN109311812 A CN 109311812A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明公开了一类作为c‑MET抑制剂的吡啶酮类化合物，具体公开了式(Ⅰ)所示化合物或其药学上可接受的盐。
Description
PCT国内申请，说明书已公开。
Claims (17)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610954377 | 2016-10-27 | ||
| CN201610954377X | 2016-10-27 | ||
| PCT/CN2017/107964 WO2018077227A1 (zh) | 2016-10-27 | 2017-10-27 | 作为c-MET抑制剂的吡啶酮类化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109311812A true CN109311812A (zh) | 2019-02-05 |
| CN109311812B CN109311812B (zh) | 2020-03-17 |
Family
ID=62024383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780036464.XA Active CN109311812B (zh) | 2016-10-27 | 2017-10-27 | 作为c-MET抑制剂的吡啶酮类化合物 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10501443B2 (zh) |
| EP (1) | EP3533787B1 (zh) |
| JP (1) | JP6719679B2 (zh) |
| KR (1) | KR102070748B1 (zh) |
| CN (1) | CN109311812B (zh) |
| AU (1) | AU2017348810B2 (zh) |
| BR (1) | BR112019008415B1 (zh) |
| CA (1) | CA3041164C (zh) |
| CO (1) | CO2019005165A2 (zh) |
| DK (1) | DK3533787T3 (zh) |
| EA (1) | EA038108B1 (zh) |
| ES (1) | ES2835301T3 (zh) |
| HR (1) | HRP20201985T1 (zh) |
| HU (1) | HUE051734T2 (zh) |
| IL (1) | IL266126B (zh) |
| LT (1) | LT3533787T (zh) |
| MX (1) | MX374439B (zh) |
| MY (1) | MY189557A (zh) |
| PE (1) | PE20190912A1 (zh) |
| PH (1) | PH12019500875B1 (zh) |
| PL (1) | PL3533787T3 (zh) |
| PT (1) | PT3533787T (zh) |
| RS (1) | RS61126B1 (zh) |
| SG (1) | SG11201903801YA (zh) |
| SI (1) | SI3533787T1 (zh) |
| UA (1) | UA122737C2 (zh) |
| WO (1) | WO2018077227A1 (zh) |
| ZA (1) | ZA201903074B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112004801A (zh) * | 2018-04-26 | 2020-11-27 | 福建广生堂药业股份有限公司 | 一种c-MET 抑制剂的晶型及其盐型和制备方法 |
| CN116171156A (zh) * | 2020-07-31 | 2023-05-26 | 南京明德新药研发有限公司 | 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3803401A4 (en) * | 2018-05-30 | 2022-02-23 | Promega Corporation | BROAD SPECTRUM KINASE BINDERS |
| KR102660608B1 (ko) * | 2019-02-01 | 2024-04-26 | 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. | c-Met억제제로서 피리미디닐기를 포함하는 삼환식 화합물 |
| WO2022063869A2 (en) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| IL309014A (en) | 2021-06-04 | 2024-01-01 | Merck Patent Gmbh | Compounds for the treatment of glioblastoma |
| CR20250458A (es) | 2023-03-30 | 2025-11-21 | Revolution Medicines Inc | Composiciones para inducir la hidrólisis de ras gtp y sus usos |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101743241A (zh) * | 2007-07-12 | 2010-06-16 | 默克专利有限公司 | 哒嗪酮衍生物 |
| CN104144925A (zh) * | 2011-10-17 | 2014-11-12 | 拜耳知识产权有限责任公司 | 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586418B2 (en) | 2000-06-29 | 2003-07-01 | Bristol-Myers Squibb Company | Thrombin or factor Xa inhibitors |
| US7732456B2 (en) | 2004-03-05 | 2010-06-08 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
| MX2009008531A (es) * | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| CN104203243A (zh) * | 2012-03-19 | 2014-12-10 | 默克专利股份公司 | 具有抗肿瘤活性的6-氧代-1,6-二氢-哒嗪衍生物与其他抗肿瘤化合物的组合 |
| ES2679372T3 (es) * | 2012-10-11 | 2018-08-24 | Merck Patent Gmbh | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad contra el cáncer con un inhibidor de MEK |
| SG11201704763SA (en) * | 2014-12-11 | 2017-07-28 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative |
-
2017
- 2017-10-27 MY MYPI2019002142A patent/MY189557A/en unknown
- 2017-10-27 PL PL17864813T patent/PL3533787T3/pl unknown
- 2017-10-27 WO PCT/CN2017/107964 patent/WO2018077227A1/zh not_active Ceased
- 2017-10-27 AU AU2017348810A patent/AU2017348810B2/en active Active
- 2017-10-27 HR HRP20201985TT patent/HRP20201985T1/hr unknown
- 2017-10-27 PE PE2019000855A patent/PE20190912A1/es unknown
- 2017-10-27 PT PT178648135T patent/PT3533787T/pt unknown
- 2017-10-27 KR KR1020197014236A patent/KR102070748B1/ko active Active
- 2017-10-27 CN CN201780036464.XA patent/CN109311812B/zh active Active
- 2017-10-27 UA UAA201904417A patent/UA122737C2/uk unknown
- 2017-10-27 RS RS20201448A patent/RS61126B1/sr unknown
- 2017-10-27 LT LTEP17864813.5T patent/LT3533787T/lt unknown
- 2017-10-27 BR BR112019008415-0A patent/BR112019008415B1/pt active IP Right Grant
- 2017-10-27 EP EP17864813.5A patent/EP3533787B1/en active Active
- 2017-10-27 MX MX2019004626A patent/MX374439B/es active IP Right Grant
- 2017-10-27 SG SG11201903801YA patent/SG11201903801YA/en unknown
- 2017-10-27 CA CA3041164A patent/CA3041164C/en active Active
- 2017-10-27 PH PH1/2019/500875A patent/PH12019500875B1/en unknown
- 2017-10-27 DK DK17864813.5T patent/DK3533787T3/da active
- 2017-10-27 HU HUE17864813A patent/HUE051734T2/hu unknown
- 2017-10-27 SI SI201730558T patent/SI3533787T1/sl unknown
- 2017-10-27 ES ES17864813T patent/ES2835301T3/es active Active
- 2017-10-27 JP JP2019540379A patent/JP6719679B2/ja active Active
- 2017-10-27 US US16/343,387 patent/US10501443B2/en active Active
- 2017-10-27 EA EA201990952A patent/EA038108B1/ru unknown
-
2019
- 2019-04-18 IL IL266126A patent/IL266126B/en active IP Right Grant
- 2019-05-16 ZA ZA2019/03074A patent/ZA201903074B/en unknown
- 2019-05-21 CO CONC2019/0005165A patent/CO2019005165A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101743241A (zh) * | 2007-07-12 | 2010-06-16 | 默克专利有限公司 | 哒嗪酮衍生物 |
| CN104144925A (zh) * | 2011-10-17 | 2014-11-12 | 拜耳知识产权有限责任公司 | 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112004801A (zh) * | 2018-04-26 | 2020-11-27 | 福建广生堂药业股份有限公司 | 一种c-MET 抑制剂的晶型及其盐型和制备方法 |
| AU2019260240B2 (en) * | 2018-04-26 | 2023-05-11 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor |
| CN112004801B (zh) * | 2018-04-26 | 2023-09-08 | 福建广生中霖生物科技有限公司 | 一种c-MET抑制剂的晶型及其盐型和制备方法 |
| CN116171156A (zh) * | 2020-07-31 | 2023-05-26 | 南京明德新药研发有限公司 | 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109311812A (zh) | 作为c-MET抑制剂的吡啶酮类化合物 | |
| JP2016515560A5 (zh) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2016513660A5 (zh) | ||
| JP2014508811A5 (zh) | ||
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2014521625A5 (zh) | ||
| JP2015535277A5 (zh) | ||
| JP2016517417A5 (zh) | ||
| JP2013537203A5 (zh) | ||
| JP2016503799A5 (zh) | ||
| JP2010031025A5 (zh) | ||
| JP2016531126A5 (zh) | ||
| JP2015520140A5 (zh) | ||
| JP2016540742A5 (zh) | ||
| IN2014DN07283A (zh) | ||
| JP2013502441A5 (zh) | ||
| JP2012097115A5 (zh) | ||
| JP2015536997A5 (zh) | ||
| JP2016528273A5 (zh) | ||
| RU2019121926A (ru) | Ингибитор CDK4/6 | |
| CN110891950A (zh) | 一种三嗪化合物及其药学上可接受的盐 | |
| CN109563091A (zh) | Fgfr4抑制剂及其制备方法和应用 | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| CN110225781A (zh) | 噻唑衍生物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 355399 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province Applicant after: Fujian Cosunter Pharmaceutical Co., Ltd. Address before: 350003 Block B, Building 10, Software Park B, 89 Software Avenue, Gulou District, Fuzhou City, Fujian Province Applicant before: Fujian Cosunter Pharmaceutical Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40002592 Country of ref document: HK |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20220127 Address after: 355300 building 1-7, Fuyuan Industrial Park, Zherong County, Ningde City, Fujian Province Patentee after: Fujian Guangsheng Zhonglin Biotechnology Co.,Ltd. Address before: 355399 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province Patentee before: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |